@article{45198471a20a437ca00bd8daeb8a1bac,
title = "Cerebrospinal fluid sphingolipids, β-amyloid, and tau in adults at risk for Alzheimer's disease",
abstract = "Cellular studies suggest sphingolipids may cause or accelerate amyloid-beta (Aβ) and tau pathology but invivo human studies are lacking. We determined cerebrospinal fluid levels of sphingolipids (ceramides and sphingomyelins), amyloid-beta (Aβ1-42, AβX-38, AβX-40, and AβX-42) and tau (T-tau and p-tau181) in 91 cognitively normal individuals, aged 36-69years, with a parental history of Alzheimer's disease. The 18-carbon acyl chain length ceramide species was associated with AβX-38 (. r= 0.312, p= 0.003), AβX-40 (. r= 0.327, p= 0.002), and T-tau (. r= 0.313, p= 0.003) but not with AβX-42 (. r= 0.171, p= 0.106) or p-tau (. r= 0.086, p= 0.418). All sphingomyelin species correlated (most p < 0.001) with all Aβ species and T-tau many also correlated with p-tau. Results remained in regression models after controlling for age and APOE genotype. These results suggest invivo relationships between cerebrospinal fluid ceramides and sphingomyelins and Aβ and tau levels in cognitively normal individuals at increased risk for Alzheimer's disease, indicating these sphingolipids may be associated with early pathogenesis.",
keywords = "Alzheimer's disease, Beta-amyloid, Ceramide, Cerebrospinal fluid, Sphingolipids, Sphingomyelin, Tau",
author = "Mielke, {Michelle M.} and Haughey, {Norman J.} and Bandaru, {Veera V.R.} and Henrik Zetterberg and Kaj Blennow and Ulf Andreasson and Johnson, {Sterling C.} and Gleason, {Carey E.} and Blazel, {Hanna M.} and Luigi Puglielli and Sager, {Mark A.} and Sanjay Asthana and Carlsson, {Cynthia M.}",
note = "Funding Information: Dr Mielke receives research support from the NIH/NIA and has served as a consultant for Eli Lilly . Dr Haughey receives grant funding from NIH . Dr Bandaru, Dr Zetterberg, Dr Andreasson, Dr Gleason, and Ms Blazel have no disclosures to report. Dr Johnson receives grant funding from NIH and the Department of Veterans Affairs . Dr Puglielli receives grant funding from NIH and the Department of Veterans Affairs . Dr Sager receives grant funding from NIH and the Helen Bader Foundation , Milwaukee, WI, USA. Dr Asthana receives grant funding from NIH and serves as a site PI for Alzheimer's disease treatment trials sponsored by Elan , Merck and Co, Inc , Pfizer , and Wyeth . Dr Carlsson receives research support from the NIH/NIA , NIH/NINR , HRSA , and the University of Wisconsin, Department of Medicine . Funding Information: This study was supported in part by the National Institutes of Health (grants AG026752 , AG027161 , 1UL1RR025011 , AG033514 , U01 AG037526 , AA0017408 , MH077542 , MH075673 , and AG034849 ) and pilot funding from the University of Wisconsin, Department of Medicine . Publisher Copyright: {\textcopyright} 2014 Elsevier Inc.",
year = "2014",
month = nov,
day = "1",
doi = "10.1016/j.neurobiolaging.2014.05.019",
language = "English (US)",
volume = "35",
pages = "2486--2494",
journal = "Neurobiology of aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",
number = "11",
}